BiotechTube

Nirmatrelvir + Ritonavir + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Long COVID

Conditions

Long COVID

Trial Timeline

Apr 14, 2023 → Aug 21, 2024

NCT ID
NCT05668091

About Nirmatrelvir + Ritonavir + Placebo

Nirmatrelvir + Ritonavir + Placebo is a phase 2 stage product being developed by Pfizer for Long COVID. The current trial status is completed. This product is registered under clinical trial identifier NCT05668091. Target conditions include Long COVID.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05668091Phase 2Completed

Competing Products

16 competing products in Long COVID

See all competitors
ProductCompanyStageHype Score
EnsitrelvirShionogiPhase 2
52
TBM100NovartisApproved
85
GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + DofetilideGilead SciencesPhase 1
32
EleclazineGilead SciencesPhase 1
32
EleclazineGilead SciencesPhase 1
32
Placebo + RanolazineGilead SciencesPhase 2
51
GS-6615Gilead SciencesPhase 1
32
Eleclazine + Eleclazine placeboGilead SciencesPhase 3
76
Staccato alprazolamUCBPhase 3
74
Staccato alprazolamUCBPhase 3
74
N-803 (IL-15 Superagonist)ImmunityBioPhase 2
49
AnktivaImmunityBioPhase 2
49
UX007Ultragenyx PharmaceuticalPhase 2
47
triheptanoinUltragenyx PharmaceuticalPre-clinical
18
TriheptanoinUltragenyx PharmaceuticalPhase 3
72
TriheptanoinUltragenyx PharmaceuticalPre-clinical
18

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84